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Abstract 5 
Background and purpose: Current automated planning methods do not allow for the intuitive exploration of clinical trade-offs 6 
during calibration. Recently a novel automated planning solution, which is calibrated using Pareto navigation principles, has been 7 
developed to address this issue. The purpose of this work was to clinically validate the solution for prostate cancer patients with 8 
and without elective nodal irradiation.  9 
Materials and methods: For 40 randomly selected patients (20 prostate and seminal vesicles (PSV) and 20 prostate and pelvic 10 
nodes (PPN)) automatically generated plans (VMATAuto) were compared against plans created by expert dosimetrists under clinical 11 
conditions (VMATClinical) and no time pressures (VMATIdeal).  Plans were compared through quantitative comparison of dosimetric 12 
parameters and blind review by an oncologist. 13 
Results: Upon blind review 39/40 and 33/40 VMATAuto plans were considered preferable or equal to VMATClinical and VMATIdeal 14 
respectively, with all deemed clinically acceptable. Dosimetrically, VMATAuto, VMATClinical and VMATIdeal were similar, with observed 15 
differences generally of low clinical significance. Compared to VMATClinical, VMATAuto reduced hands-on planning time by 94% and 16 
79% for PSV and PPN respectively. Total planning time was significantly reduced from 22.2 mins to 14.0 mins for PSV, with no 17 
significant reduction observed for PPN. 18 
Conclusions: A novel automated planning solution has been evaluated, whose Pareto navigation based calibration enabled clinical 19 
decision-making on trade-off balancing to be intuitively incorporated into automated protocols. It was successfully applied to two 20 
sites of differing complexity and robustly generated high quality plans in an efficient manner.  21 
Introduction 22 
Intensity modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT) treatment plan generation is a complex 23 
process, traditionally performed manually by medical physicists or specialist dosimetrists. Manual methods can be time consuming 24 
and dependent on the treatment planner’s experience [1]. A solution to this problem is automated planning, where high quality 25 
plans are generated autonomously with minimal operator interaction [2–9].  26 
A key challenge in automated planning is incorporating treatment planners’ or oncologists’ clinical experience and decision-making 27 
within the autonomous process. A number of different methods have been employed: knowledge based planning (KBP) utilises 28 
databases of previous clinical plans to correlate the relationship between patient geometry and the resultant dose distribution, 29 
which then informs the optimisation of new patients [3,10–13]; sequential ε-constraint planning (εc) optimises plans based on a 30 
list of clinically prioritised goals [2,7,8,14–16]; and protocol based automatic iterative optimisation (PB-AIO) adapts optimisation 31 
parameters during the planning process, tailoring the optimisation to the individual patient [4,17–19]. Whilst these techniques 32 
have been successfully applied to automated planning, a method for intuitive exploration of different ‘trade-off’ options during 33 
their calibration has not yet been demonstrated.   34 
Recently we developed a fully automated treatment planning solution, which is uniquely calibrated using Pareto navigation 35 
principles. This novel calibration process allows differing trade-off options to be intuitively explored, ensuring clinical experience 36 
and decision-making can be effectively incorporated into the autonomous plan generation process. Utilisation of Pareto navigation 37 
techniques on a per patient basis has been shown to improve congruence between the oncologist’s clinical preference and the 38 
final clinical plan [20], improve efficiency [20–22], and enable novice operators to generate high quality plans [21]. It is anticipated 39 
that utilising such an approach to inform and calibrate an automated solution would have similar benefits and provide significant 40 
advantages over current methods, which are reliant on trial and error, or calibration against historical datasets.  41 
In a previous publication we presented in detail the algorithms behind our automated approach, demonstrated the calibration 42 
process for the tumour site of prostate and seminal vesicles (PSV), and presented results from a limited proof of principle pilot 43 
study on 10 patients [23]. The objective of this study was to additionally calibrate the solution for the complex site of prostate and 44 
pelvic nodes (PPN), and for both PSV and PPN perform a comprehensive clinical evaluation comparing this new automated 45 
technique with plans generated manually by expert dosimetrists. It is hypothesised that this novel approach to calibration will 46 
result in high quality plans that are closely aligned with oncologist clinical preferences.   47 
Methods and Materials  48 
Patient Selection and Planning Protocol 49 
Calibration for the tumour site of PPN was performed on a dataset of 20 previously treated patients at Velindre Cancer Centre; 10 50 
randomly selected from patients treated between July and December 2015 and 10 selected from a previous research database of 51 
patients treated between June and September 2014. The subsequent evaluative study was performed on an independent 52 
validation dataset of 40 subjects (20 PSV and 20 PPN) which were randomly selected from patients treated at Velindre Cancer 53 
Centre between January and June 2016.  54 
Patients were planned on computed tomography scans with 3mm slice thickness. Prostate, seminal vesicles (SV), rectum, bladder, 55 
bowel, pelvic nodes (PPN only) and an optional pelvic node boost volume covering gross nodal disease (PPN only) were delineated 56 
prior to planning. The following planning target volumes (PTV) were subsequently generated: prostate, pelvic nodes and pelvic 57 
node boost expanded by 5 mm (6 mm craniocaudally) to form PTV60, PTV44 (PPN only)  and PTV50 (PPN only)  respectively; and 58 
prostate + SV expanded isotropically by 10 mm to form PTV48. For automated plan generation an additional volume, 59 
BowelBagRegion, was manually delineated for PPN, with details provided in the supplementary file S1.    60 
Treatments were prescribed for 20 fractions using a simultaneous integrated boost (SIB) technique, with the PTV’s suffix denoting 61 
its prescribed dose in Gy. The local clinical planning goals, adapted from the UK clinical trial PIVOTAL [24], are detailed in the 62 
supplementary file S2.  All plans in this study were generated within RayStation (v4.99, Raysearch Laboratories, Stockholm) using 63 
identical computer clients, treatment units (Elekta Agility, Elekta Ltd, Crawley) and VMAT arc configurations (6MV single 360° arc 64 
for PSV; 6MV dual 360° arc for PPN). 65 
Automated System Overview 66 
Automated planning was performed using EdgeVcc: an ‘in-house’ automated treatment planning solution, implemented within 67 
RayStation using its scripting functionality. This section provides an brief overview of the system, with full technical details 68 
provided by Wheeler et al [23]. 69 
Prior to automated plan generation a site-specific ‘AutoPlan protocol’ must be created and calibrated. The AutoPlan protocol 70 
specifies the treatment modality, beam arrangement and planning goals for a given tumour site. Planning goals are split into three 71 
priority levels: primary normal tissue goals (P1), target goals (P2) and trade-off goals (P3). The planning goals used in this study for 72 
PPN are presented in the supplementary file S3.  73 
Planning goals do not require any user defined optimisation weighting factors, instead weights are automatically assigned during 74 
plan generation through one of two processes. For P1 and P2 goals, where the handling of competing clinical trade-offs is explicitly 75 
defined (i.e. target coverage is compromised to maintain normal tissue goals), weights are derived from a set of hard-coded 76 
nominal weights, which are common to all tumour sites. When derived, weighting factors are scaled according to the volume of 77 
their corresponding region of interest to account for the observation that to obtain the same effect, small volumes require lower 78 
weighting factors than large volumes.  For P3 goals, interaction between conflicting trade-offs is complex, site specific and requires 79 
careful balancing of competing clinical demands. P3 nominal weights are therefore derived through an intuitive Pareto navigation 80 
based calibration process, where the operator sequentially explores differently weighted options of each P3 goal using an 81 
interactive slider GUI, with DVHs and dose distributions updated in real-time to inform the decision-making. The calibration is 82 
initially performed on a single patient, with the resultant solution tested against the remaining patients in the calibration cohort 83 
to ensure robustness against the whole population. Where there are large inter-patient anatomical variations, repeat navigations 84 
over population outliers may be required to improve the robustness of the solution. In this situation the operator decides if the 85 
final weighting is based a particular patient, or averaged over multiple patients. Once calibrated, a single high quality treatment 86 
plan can be automatically generated for delineated patients within that tumour site.  87 
Treatment plans are generated using RayStation’s native optimiser with optimisation objectives derived from the defined planning 88 
goals. Plan optimisation is based on a PB-AIO framework where the target values and weights of P3 related objectives are 89 
dynamically adjusted during the optimisation, such that the plan is tailored to the individual patient. Implementation of ‘dynamic 90 
objectives’ ensures P3 goals are always acted on by the optimiser and thus minimised, and additionally is hypothesised to enable 91 
a common set of calibration weights to be applicable across all patients for a given site. 92 
Automated Plan Generation 93 
Using the calibration patient dataset an AutoPlan protocol for PPN was created and calibrated. The final PPN protocol and 94 
previously calibrated PSV protocol [23] were used to generate a single automated plan (VMATAuto) for each patient in the 95 
corresponding independent validation datasets. Plans were reviewed for clinical acceptability, with manual dose scaling 96 
performed if required. All work was performed by a single clinical scientist (PW). 97 
Study Design and Statistical Analysis 98 
To benchmark VMATAuto, experienced IMRT/VMAT dosimetrists (CJ for PSV; OW for PPN) generated two manual treatment plans 99 
(VMATClinical & VMATIdeal) for each patient in the validation dataset. VMATClinical was generated under simulated clinical conditions 100 
following standard protocols, which utilise an efficient template-based class-solution methodology. As per clinical practice the 101 
dosimetrist ceased optimising once a clinically acceptable plan was generated. Then, in the absence of time pressure, the 102 
dosimetrist used their knowledge and expertise to improve VMATClinical as far as they deemed possible to produce an ‘ideal’ 103 
treatment plan, VMATIdeal. 104 
Prior to manual plan generation and the calibration of both AutoPlan protocols, all operators were briefed on trade-off 105 
prioritisation via discussions with a consultant oncologist assigned to each clinical site (JS for PSV; NP for PPN). For all three 106 
techniques operator hands-on and total planning times were recorded. 107 
VMATAuto was compared to both VMATClinical and VMATIdeal in terms of plan quality and planning efficiency. Plan quality was 108 
quantitatively assessed using local clinical planning goals; and D98%, D2% and Paddick’s Conformity Index (CI) [25] for each target 109 
volume. Two-sided Wilcoxon matched-paired signed-rank tests assessed the statistical significance of any differences in plan 110 
quality and timing metrics. In addition, a blinded qualitative assessment was performed by the assigned oncologist to: score overall 111 
plan quality using a five point scale (1-unacceptable, 2-poor, 3-satisfactory, 4-good, 5-excellent); establish the clinical acceptability 112 
of each plan; and rank the trio of plans in order of preference, with clinically equivalent plans given equal rank.  113 
Results 114 
Calibration for the complex site of PPN was challenging and iterative due to the high number of competing trade-offs and large 115 
inter-patient variability in OAR volumes. Over 40 individual navigations across six patients were performed. During PPN calibration 116 
the hard coded P1 nominal weight for primary conformality goals was considered suboptimal and manually increased to match 117 
the weight for P1 primary OAR goals. The post calibration nominal weights are presented in the supplementary file S4. 118 
39/40 VMATAuto plans were generated with no user intervention; for one PPN patient the plan MU was scaled by 0.3% to ensure 119 
PTV44 D99% was within the local clinical planning goal. A summary of the quantitative plan comparison is presented in Table 1 120 
and Fig. 1, with example dose distributions presented in Fig. 2. For both PPN and PSV, VMATIdeal led to small reductions in all OAR 121 
metrics when compared to VMATClinical and across all three techniques observed differences were generally considered of low 122 
clinical significance. For PSV VMATAuto, the noteworthy statistically significant (p<0.05) differences with VMATIdeal and VMATClinical 123 
were: reductions in rectum mean dose and V24.3Gy, increases in the majority of bladder metrics, improved (increased) CI 124 
compared to VMATClinical, and decreased CI compared to VMATIdeal. For PPN VMATAuto the noteworthy differences (p<0.05) were: 125 
reduction in bowel V36.5Gy; increased mean bladder dose; increased PTV48 CI; and when compared to VMATClinical only, decreased 126 
rectum V24.3Gy. For PSV, automation led to a moderate increase in plan MU of 7% and 9% compared to VMATIdeal and VMATClinical 127 
respectively, which may be indicative of increased modulation. 128 
All 120 plans were considered acceptable upon blind review by the oncologist, with plan quality scores either good (4) or excellent 129 
(5). Analysis of the plan ranking determined that 39/40 and 33/40 of VMATAuto plans were considered preferable or equal to 130 
VMATClinical and VMATIdeal respectively. When compared to VMATClinical, hands-on planning time was significantly reduced by 94% 131 
and 79% for PSV and PPN respectively. Total planning time was significantly reduced from 22.2mins to 14.0mins for PSV, with no 132 
significant reduction observed for PPN.  133 
Discussion 134 
In this study a novel automated treatment planning solution, which is directly calibrated using Pareto navigation principles, has 135 
been robustly validated for prostate cancer. The resultant automated protocols were rigorously evaluated against plans generated 136 
by expert dosimetrists, with favourable results towards automation. Furthermore the solution’s robustness to treatment site 137 
complexity was validated through application to PPN; a treatment site with up to four PTV prescription levels and wide inter-138 
patient OAR volume variation. 139 
In our previous work we demonstrated that for the simple site of PSV, Pareto navigation enabled both the intuitive exploration of 140 
competing trade-offs and the creation of a high quality solution in a time efficient manner; benefits which are congruent with 141 
Pareto navigation applied on a per patient basis [20–22]. In this study the generalisability and versatility of the calibration 142 
methodology was demonstrated through successful application to PPN, a site of significant complexity. As with PSV, the intuitive 143 
exploration of trade-offs was considered a key benefit in ensuring alignment between the final automated solution and the 144 
oncologist’s clinical aims. However, due to wide variations in inter-patient anatomy the calibration was more iterative and 145 
challenging, with additional navigations required over population outliers. This is in contrast to PSV where navigation over a single 146 
patient was sufficient for successful protocol calibration [23].  147 
During the calibration process several potential improvements in the implemented methodology were identified. Firstly, the hard-148 
coded objective weights for P1 and P2, which were based on previous clinical experience, may need further refining, as evidenced 149 
by the requirement to increase the nominal weight for P1 primary conformality goals for PPN. Secondly, challenges during the PPN 150 
calibration indicated that the optimum calibration weights for a given patient were still correlated with anatomical geometry, 151 
even when objective positions and weights were dynamically adjusted. Further work will include assessing and correcting for this 152 
correlation using machine learning. 153 
The evaluative study demonstrated that when compared to manual planning under clinical conditions, VMATAuto was the superior 154 
technique both in terms of quality and efficiency. In addition, results indicate VMATAuto is non-inferior to manual planning by 155 
expert dosimetrists under no time pressure. In general, dosimetric differences between VMATIdeal and VMATAuto were small, which 156 
was considered supportive evidence that implementation of ‘dynamic objectives’ within the automated planning process were 157 
yielding plans which were, or were near to, Pareto optimal.  158 
Interestingly clinical preference towards automation was stronger for the more complex site of PPN. It is hypothesised that for 159 
PPN the high degrees of freedom within the optimisation problem made the manual trial and error exploration of trade-offs 160 
difficult. In contrast, implementation of Pareto navigation techniques allowed intuitive exploration of these trade-offs and whilst 161 
calibration was challenging, this approach resulted in plans more closely aligned to the clinician’s preference. Improved 162 
congruence with the clinician’s clinical preference is a key benefit of Pareto navigation, which has been demonstrated on a per-163 
patient level [20] and this work supports the hypothesis that similar benefits can be realised by applying this technique at a patient 164 
cohort level.  165 
A potential limitation of this study is its tightly controlled study design, in that for each treatment site all manual planning was 166 
performed by a single treatment planner, and guidance on trade-off balancing and the subsequent blind review was performed 167 
by a single oncologist. The study was designed such that inter-observer bias was minimised, however as a consequence results 168 
may not be directly translatable to clinical practice where inter-observer variability in manual plan quality and oncologist trade-169 
off preferences may be significant.   170 
Compared to existing methods of calibrating automated solutions, Pareto navigation presents a clear alternative. For both εc and 171 
PB-AIO, automated solution calibrations are reliant on trial and error. It is envisaged that the methods presented in this study 172 
would enhance many of the existing εc and PB-AIO solutions and bring the advantages of intuitive trade-off exploration into the 173 
wider field of automated planning. When compared to KBP, the employed calibration methodology benefits from having no 174 
requirement for a database of reference treatment plans. Automated solutions are therefore not influenced by the quality or 175 
quantity of historical plans and new techniques can be developed without the time consuming manual creation of a training 176 
dataset. In addition, it is envisaged that due to flexibility in the calibration process this approach is ideal for successful 177 
implementation in radiotherapy centres with differing clinical protocols. 178 
When comparing to previously published studies, for the tumour site of PSV a thorough summary has recently been presented by 179 
Heijmen et al [26]; with 12 studies identified as demonstrating small differences between automated and manual plans 180 
[2,10,18,27–35], and only their more recent multi-centre study showing the overall dosimetric superiority of automation through 181 
reduced rectum doses [26]. For PPN, to the authors’ knowledge two studies have been published. The first being a methodological 182 
paper presenting results from a single patient [36], which will not be discussed further, and the second a 30 patient evaluative 183 
study comparing automated planning using εc with manual planning under no time pressures [8]. The study demonstrated a clear 184 
preference towards automated planning, with notable improvements in a wide range of dosimetric parameters. Direct comparison 185 
between these examples in the literature and results from the study presented in this manuscript is not possible or appropriate 186 
due to the wide range of confounding factors including: patient selection criteria, planner and institutional expertise, and clinical 187 
protocol complexity. However, what can be ascertained is that results from this study, which demonstrate that automated 188 
planning is non-inferior to expert manual planning, are consistent with existing literature and supportive of Pareto navigation 189 
guided automated planning. Furthermore, in a recent review on automated planning by Hussein et al [37] only two out of the 81 190 
identified evaluative studies were for complex pelvis treatments (SIB technique with nodal irradiation) [8,38]. Our work builds on 191 
this limited evidence base, providing further data in support of automation for even the most complex tumour sites. 192 
Conclusions 193 
EdgeVcc is a versatile new automated planning solution whose unique Pareto navigation based calibration methodology enabled 194 
clinical decision-making on trade-off balancing to be intuitively incorporated within automated protocols. It has been successfully 195 
applied to two sites of differing complexity and robustly generates high quality plans in an efficient manner.  196 
Acknowledgements 197 
This research is funded by Health and Care Research Wales and sponsored by Velindre NHS Trust.  198 
Conflicts of Interest 199 
The authors declare that they have no conflicts of interest. 200 
References 201 
[1] Nelms BE, Robinson G, Markham J, Velasco K, Boyd S, Narayan S, et al. Variation in external beam treatment plan quality: 202 
An inter-institutional study of planners and planning systems. Pract Radiat Oncol 2012;2:296–305. 203 
doi:10.1016/j.prro.2011.11.012. 204 
[2] Voet PWJ, Dirkx MLP, Breedveld S, Al-Mamgani A, Incrocci L, Heijmen BJM. Fully automated volumetric modulated arc 205 
therapy plan generation for prostate cancer patients. Int J Radiat Oncol Biol Phys 2014;88:1175–9. 206 
doi:10.1016/j.ijrobp.2013.12.046. 207 
[3] Wu B, McNutt T, Zahurak M, Simari P, Pang D, Taylor R, et al. Fully automated simultaneous integrated boosted-intensity 208 
modulated radiation therapy treatment planning is feasible for head-and-neck cancer: A prospective clinical study. Int J 209 
Radiat Oncol Biol Phys 2012;84:e647–53. doi:10.1016/j.ijrobp.2012.06.047. 210 
[4] Song Y, Wang Q, Jiang X, Liu S, Zhang Y, Bai S. Fully automatic volumetric modulated arc therapy plan generation for rectal 211 
cancer. Radiother Oncol 2016;119:531–6. doi:10.1016/j.radonc.2016.04.010. 212 
[5] Hansen CR, Bertelsen A, Hazell I, Zukauskaite R, Gyldenkerne N, Johansen J, et al. Automatic treatment planning improves 213 
the clinical quality of head and neck cancer treatment plans. Clin Transl Radiat Oncol 2016;1:1–7. 214 
doi:10.1016/j.ctro.2016.08.001. 215 
[6] Purdie TG, Dinniwell RE, Fyles A, Sharpe MB. Automation and Intensity Modulated Radiation Therapy for Individualized 216 
High-Quality Tangent Breast Treatment Plans. Int J Radiat Oncol Biol Phys 2014;90:688–95. 217 
doi:10.1016/j.ijrobp.2014.06.056. 218 
[7] Sharfo AWM, Stieler F, Kupfer O, Heijmen BJM, Dirkx MLP, Breedveld S, et al. Automated VMAT planning for postoperative 219 
adjuvant treatment of advanced gastric cancer. Radiat Oncol 2018;13:74. doi:10.1186/s13014-018-1032-z. 220 
[8] Buschmann M, Sharfo AWM, Penninkhof J, Seppenwoolde Y, Goldner G, Georg D, et al. Automated volumetric modulated 221 
arc therapy planning for whole pelvic prostate radiotherapy. Strahlenther Onkol 2017:333–42. doi:10.1007/s00066-017-222 
1246-2. 223 
[9] Quan EM, Chang JY, Liao Z, Xia T, Yuan Z, Liu H, et al. Automated volumetric modulated arc therapy treatment planning 224 
for stage III lung cancer: How does it compare with intensity-modulated radio therapy? Int J Radiat Oncol Biol Phys 225 
2012;84:e69–76. doi:10.1016/j.ijrobp.2012.02.017. 226 
[10] Yang Y, Ford EC, Wu B, Pinkawa M, van Triest B, Campbell P, et al. An overlap-volume-histogram based method for rectal 227 
dose prediction and automated treatment planning in the external beam prostate radiotherapy following hydrogel 228 
injection. Med Phys 2013;40:011709. doi:10.1118/1.4769424. 229 
[11] Wu B, Pang D, Simari P, Taylor R, Sanguineti G, McNutt T. Using overlap volume histogram and IMRT plan data to guide 230 
and automate VMAT planning: a head-and-neck case study. Med Phys 2013;40:021714. doi:10.1118/1.4788671. 231 
[12] Mcintosh C, Welch M, Mcniven A. Fully automated treatment planning for head and neck radiotherapy using a voxel-based 232 
dose prediction and dose mimicking method 2017;62:5926–44. 233 
[13] Fan J, Wang J, Chen Z, Hu C, Zhang Z, Hu W. Automatic treatment planning based on three-dimensional dose distribution 234 
predicted from deep learning technique. Med Phys 2018. doi:10.1002/mp.13271. 235 
[14] Breedveld S, Storchi PRM, Voet PWJ, Heijmen BJM. iCycle: Integrated, multicriterial beam angle, and profile optimization 236 
for generation of coplanar and noncoplanar IMRT plans. Med Phys 2012;39:951–63. doi:10.1118/1.3676689. 237 
[15] Sharfo AWM, Voet PWJ, Breedveld S, Mens JWM, Hoogeman MS, Heijmen BJM. Comparison of VMAT and IMRT strategies 238 
for cervical cancer patients using automated planning. Radiother Oncol 2015;114:395–401. 239 
doi:10.1016/j.radonc.2015.02.006. 240 
[16] Voet PWJ, Dirkx MLP, Breedveld S, Fransen D, Levendag PC, Heijmen BJM. Toward fully automated multicriterial plan 241 
generation: A prospective clinical study. Int J Radiat Oncol Biol Phys 2013;85:866–72. doi:10.1016/j.ijrobp.2012.04.015. 242 
[17] Zhang X, Li X, Quan EM, Pan X, Li Y. A methodology for automatic intensity-modulated radiation treatment planning for 243 
lung cancer. Phys Med Biol 2011;56:3873–93. doi:10.1088/0031-9155/56/13/009. 244 
[18] Winkel D, Bol GH, van Asselen B, Hes J, Scholten V, Kerkmeijer LGW, et al. Development and clinical introduction of 245 
automated radiotherapy treatment planning for prostate cancer. Phys Med Biol 2016;61:8587–95. doi:10.1088/1361-246 
6560/61/24/8587. 247 
[19] Vanderstraeten B, Goddeeris B, Vandecasteele K, van Eijkeren M, De Wagter C, Lievens Y. Automated instead of manual 248 
treatment planning? A plan comparison based on dose-volume statistics and clinical preference. Int J Radiat Oncol 2018;In 249 
Press. doi:10.1016/j.ijrobp.2018.05.063. 250 
[20] Craft DL, Hong TS, Shih HA, Bortfeld TR. Improved planning time and plan quality through multicriteria optimization for 251 
intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2012;82:83–90. doi:10.1016/j.ijrobp.2010.12.007. 252 
[21] Kierkels RG, Visser R, Bijl HP, Langendijk JA, van ‘t Veld AA, Steenbakkers RJ, et al. Multicriteria optimization enables less 253 
experienced planners to efficiently produce high quality treatment plans in head and neck cancer radiotherapy. Radiat 254 
Oncol 2015;10. doi:10.1186/s13014-015-0385-9. 255 
[22] Liao X, Lang J, Li N, Wang P, Li J, Yang J, et al. Dosimetric comparisons of IMRT planning using MCO and DMPO techniques. 256 
Technol. Heal. Care, vol. 25, 2017, p. S107–14. doi:10.3233/THC-171312. 257 
[23] Wheeler PA, Chu M, Holmes R, Smyth M, Maggs R, Spezi E, et al. Utilisation of Pareto navigation techniques to calibrate a 258 
fully automated radiotherapy treatment planning solution. Phys Imag Radiat Oncol 2019;10:41–8. 259 
doi:10.1016/j.phro.2019.04.005. 260 
[24] Dearnaley D, Griffin C, Harris V, Lewis R, Mayles P, Scrase C, et al. OC-0155: First toxicity results of a phase II randomised 261 
trial of prostate and pelvis versus prostate alone radiotherapy. Radiother Oncol 2017;111:S59–60. doi:10.1016/S0167-262 
8140(15)30260-7. 263 
[25] Paddick I. A simple scoring ratio to index the conformity of radiosurgical treatment plans. J Neurosurg 2000;93:219–22. 264 
[26] Heijmen B, Voet P, Fransen D, Penninkhof J, Milder M, Akhiat H, et al. Fully automated, multi-criterial planning for 265 
Volumetric Modulated Arc Therapy – An international multi-center validation for prostate cancer. Radiother Oncol 266 
2018;128:343–8. doi:10.1016/j.radonc.2018.06.023. 267 
[27] Good D, Lo J, Lee WR, Wu QJ, Yin FF, Das SK. A knowledge-based approach to improving and homogenizing intensity 268 
modulated radiation therapy planning quality among treatment centers: An example application to prostate cancer 269 
planning. Int J Radiat Oncol Biol Phys 2013;87:176–81. doi:10.1016/j.ijrobp.2013.03.015. 270 
[28] Fogliata A, Belosi F, Clivio A, Navarria P, Nicolini G, Scorsetti M, et al. On the pre-clinical validation of a commercial model-271 
based optimisation engine : Application to volumetric modulated arc therapy for patients with lung or prostate cancer. 272 
Radiother Oncol 2014;113:385–91. doi:10.1016/j.radonc.2014.11.009. 273 
[29] Nwankwo O, Mekdash H, Sihono DSK, Wenz F, Glatting G. Knowledge-based radiation therapy (KBRT) treatment planning 274 
versus planning by experts: validation of a KBRT algorithm for prostate cancer treatment planning. Radiat Oncol 275 
2015;10:111. doi:10.1186/s13014-015-0416-6. 276 
[30] Nawa K, Haga A, Nomoto A, Sarmiento R a., Shiraishi K, Yamashita H, et al. Evaluation of a commercial automatic treatment 277 
planning system for prostate cancers. Med Dosim 2017;42:203–9. doi:10.1016/j.meddos.2017.03.004. 278 
[31] Kubo K, Monzen H, Ishii K, Tamura M, Kawamorita R, Sumida I, et al. Dosimetric comparison of RapidPlan and manually 279 
optimized plans in volumetric modulated arc therapy for prostate cancer. Phys Med 2017;44:199–204. 280 
doi:10.1016/j.ejmp.2017.06.026. 281 
[32] Schubert C, Waletzko O, Weiss C, Voelzke D, Toperim S, Roeser A, et al. Intercenter validation of a knowledge based model 282 
for automated planning of volumetric modulated arc therapy for prostate cancer. The experience of the German RapidPlan 283 
Consortium. PLoS One 2017;12:1–13. doi:10.1371/journal.pone.0178034. 284 
[33] Chanyavanich V, Das SK, Lee WR, Lo JY. Knowledge-based IMRT treatment planning for prostate cancer. Med Phys 285 
2011;38:2515–22. doi:10.1118/1.3574874. 286 
[34] Hussein M, South CP, Barry M a., Adams EJ, Jordan TJ, Stewart AJ, et al. Clinical validation and benchmarking of knowledge-287 
based IMRT and VMAT treatment planning in pelvic anatomy. Radiother Oncol 2016;120:473–9. 288 
doi:10.1016/j.radonc.2016.06.022. 289 
[35] Yang J, Zhang P, Zhang L, Shu H, Li B, Gui Z. Particle swarm optimizer for weighting factor selection in intensity-modulated 290 
radiation therapy optimization algorithms. Phys Med 2017;33:136–45. doi:10.1016/j.ejmp.2016.12.021. 291 
[36] Xhaferllari I, Wong E, Bzdusek K, Lock M, Chen J. Automated IMRT planning with regional optimization using planning 292 
scripts. J Appl Clin Med Phys 2013;14:4052. doi:10.1120/jacmp.v14i1.4052. 293 
[37] Hussein M, Heijmen BJM, Verellen D, Nisbet A. Automation in intensity modulated radiotherapy treatment planning—a 294 
review of recent innovations. Br J Radiol 2018;91:20180270. doi:10.1259/bjr.20180270. 295 
[38] Wu H, Jiang F, Yue H, Li S, Zhang Y. A dosimetric evaluation of knowledge-based VMAT planning with simultaneous 296 
integrated boosting for rectal cancer patients. J Appl Clin Med Phys 2016;17:78–85. doi:10.1120/jacmp.v17i6.6410.  297 
 298 
Table 1 
Dosimetric comparison of VMATAuto, VMATClinical and VMATIdeal for the treatment sites PSV and PPN (mean ± standard deviation) 
    SVP PPN 
  Metric VMATAuto VMATClinical VMATIdeal VMATAuto VMATClinical VMATIdeal 
PTV60 D98% (Gy) 57.9 ± 0.1 57.8 ± 0.2 57.7 ± 0.1 57.8 ± 0.1 58.0 ± 0.1 57.9 ± 0.1 
  D2% (Gy) 61.6 ± 0.1 61.7 ± 0.2 61.7 ± 0.2 61.7 ± 0.1 61.9 ± 0.2 61.9 ± 0.2 
  CI 0.86 ± 0.01 0.84 ± 0.03 0.88 ± 0.02 0.82 ± 0.02 0.81 ± 0.03 0.81 ± 0.03 
PTV50 D98% (Gy)                   48.2 ± 0.2 48.0 ± 0.3 47.9 ± 0.2 
  D2% (Gy)                   52.3 ± 1.7 52.0 ± 1.0 52.1 ± 0.9 
  CI                   0.41 ± 0.05 0.41 ± 0.07 0.42 ± 0.07 
PTV48  D98% (Gy) 46.8 ± 0.5 46.8 ± 0.4 46.5 ± 0.3 46.6 ± 0.6 46.7 ± 0.4 46.6 ± 0.4 
  D2% (Gy) 58.9 ± 0.2 59.0 ± 0.3 58.6 ± 0.3 59.5 ± 0.3 59.6 ± 0.3 59.6 ± 0.3 
  CI 0.85 ± 0.01 0.82 ± 0.01 0.87 ± 0.01 0.65 ± 0.05 0.59 ± 0.07 0.60 ± 0.07 
PTV44 D98% (Gy)                   42.3 ± 0.1 42.4 ± 0.1 42.4 ± 0.1 
  D2% (Gy)                   47.4 ± 1.6 47.8 ± 1.7 47.7 ± 1.8 
  CI                   0.82 ± 0.02 0.81 ± 0.02 0.81 ± 0.02 
Rectum V24.3Gy (%) 36.7 ± 10.1 40.8 ± 11.1 38.0 ± 9.3 53.3 ± 9.3 59.3 ± 7.3 56.2 ± 8.1 
  V40.5Gy (%) 20.4 ± 7.2 20.4 ± 7.4 20.0 ± 7.2 24.0 ± 6.1 23.8 ± 6.4 23.1 ± 6.5 
  V52.7Gy (%) 8.5 ± 3.7 8.1 ± 3.6 8.0 ± 3.5 10.5 ± 3.0 10.0 ± 2.9 9.6 ± 2.9 
  V60.8Gy (%) 0.0 ± 0.1 0.0 ± 0.1 0.0 ± 0.1 0.1 ± 0.1 0.0 ± 0.1 0.0 ± 0.1 
  DMean (Gy) 22.7 ± 3.9 25.1 ± 3.5 23.4 ± 3.5 29.5 ± 2.7 30.4 ± 2.6 29.7 ± 2.6 
Bladder V40.5Gy (%) 19.2 ± 10.7 18.3 ± 9.6 17.4 ± 9.5 24.7 ± 10.4 23.7 ± 8.5 23.7 ± 8.5 
  V52.7Gy (%) 8.8 ± 5.9 8.3 ± 5.2 7.9 ± 5.2 7.4 ± 4.8 7.6 ± 4.8 7.5 ± 4.7 
  V56.8Gy (%) 6.1 ± 4.2 5.7 ± 3.8 5.6 ± 3.9 4.9 ± 3.1 5.3 ± 3.5 5.3 ± 3.5 
  DMean (Gy) 23.0 ± 9.1 22.2 ± 8.6 21.6 ± 8.6 33.0 ± 3.9 31.3 ± 3.5 31.1 ± 3.5 
Bowel V36.5Gy (cc) 0.9 ± 2.0 0.9 ± 1.9 0.7 ± 1.6 48.6 ± 35.9 53.9 ± 38.7 51.2 ± 38.0 
  V44.6Gy (cc) 0.3 ± 0.7 0.3 ± 0.8 0.3 ± 0.8 3.6 ± 6.5 3.5 ± 6.0 3.3 ± 5.6 
  V52.7Gy (cc) 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
  DMean (Gy) 8.6 ± 4.7 8.4 ± 4.7 7.7 ± 4.2 18.7 ± 2.6 19.6 ± 2.6 19.3 ± 2.4 
Patient Outline D1.8cm3 (Gy) 61.6 ± 0.1 61.7 ± 0.2 61.7 ± 0.2 61.7 ± 0.1 61.9 ± 0.3 61.9 ± 0.3 
Plan MU MU 616 ± 43 563 ± 58 575 ± 57 714 ± 60 695 ± 69 711 ± 68 
Planning Time Hands on time (mins) 1.3 ± 0.3 22.2 ± 5.3 85.4 ± 39.9 4.4 ± 0.5 20.6 ± 6.3 65.4 ± 21.1 
  Total time (mins) 14.0 ± 1.4 22.2 ± 5.3 85.4 ± 39.9 36.4 ± 3.1 41.8 ± 11.4 200.0 ± 53.1 
Plan Quality Score 5.0 ± 0.2 4.6 ± 0.5 4.9 ± 0.3 5.0 ± 0.2 4.8 ± 0.4 4.8 ± 0.4 
Plan Ranking vs  Plans Superior (%)   5% 15%   0% 20% 
VMATAuto Plans Equivalent (%)   35% 55%   35% 15% 
  Plans Inferior (%)   60% 30%   65% 65% 
Statistical significance: VMATClinical and VMATIdeal dosimetric and timing data are presented in bold where statistically significant differences 
(p<0.05) with VMATAuto are observed.  
CI: Paddick’s Conformity Index for the specified PTV.                                 
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Figure Legends 301 
 302 
Fig. 1. Comparison of rectum, bladder and bowel dosimetric plan parameters between automatically generated plans (VMATAuto) 303 
and plans generated by expert dosimetrists under no time pressure (VMATIdeal).  304 
Fig. 2.  DVH and dose distributions for patient 1 in the PPN and PSV validation cohort.  (A) PPN VMATAuto dose distribution. (B) PPN 305 
VMATIdeal dose distribution. (C) PSV VMATAuto dose distribution. (D) PSV VMATIdeal dose distribution. (E) PPN DVH for VMATAuto 306 
(solid line) and VMATIdeal (dotted line). (F) PSV DVH for VMATAuto (solid line) and VMATIdeal (dotted line). Note: BowelBagRegion 307 
ROI omitted from dose distribution images to improve clarity. 308 
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